PDPN and squamous cell carcinoma: In the case of podoplanin, all were significantly associated with a poorer survival outcome, with the exception of multivariate analysis of the OS/DSS outcome group in adenocarcinoma and univariate analysis of the OS/DSS outcome group in squamous cell carcinoma.